Cue Biopharma Inc (CUE)
1.91
-0.27
(-12.39%)
USD |
NASDAQ |
May 08, 16:00
1.91
0.00 (0.00%)
After-Hours: 19:21
Cue Biopharma Debt to Equity Ratio: 0.2202 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.2202 |
| September 30, 2023 | 0.2138 |
| June 30, 2023 | 0.2191 |
| March 31, 2023 | 0.1825 |
| December 31, 2022 | 0.1522 |
| September 30, 2022 | 0.1961 |
| June 30, 2022 | 0.1659 |
| March 31, 2022 | 0.1525 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Jun 2019
0.2202
Maximum
Dec 2023
0.0791
Average
--
Median
Jun 2019
Debt to Equity Ratio Benchmarks
| Precision BioSciences Inc | 1.188 |
| NovaBay Pharmaceuticals Inc | 0.3431 |
| Palatin Technologies Inc | 0.00 |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 61.53M |
| Total Liabilities (Quarterly) | 24.44M |
| Shareholders Equity (Quarterly) | 37.08M |
| Current Ratio | 3.012 |
| Net Debt Paydown Yield | 0.29% |